| Kindra Walker Dursteler, MD | |
|
2401 S 31st St, Temple, TX 76508-0001 | |
| (254) 724-2364 | |
| Not Available |
| Full Name | Kindra Walker Dursteler |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 7 Years |
| Location | 2401 S 31st St, Temple, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134657141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | S4293 (Texas) | Secondary |
| 207R00000X | Internal Medicine | S4293 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center Hillcrest | Waco, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hillcrest Physician Services | 1153304456 | 90 |
News Archive
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002.
A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.
South Asia is "lagging behind" in poverty and hunger reduction and is "in danger" of missing key Millennium Development Goal (MDG) targets, a U.N. official told Asian ministers gathered to discuss MDGs progress, Agence France-Presse reports. At the meeting, "senior officials told delegates from dozens of countries that global food, energy and financial crises in recent years had jeopardized progress toward achieving the goals set for 2015," the news service writes.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
› Verified 8 days ago
| Entity Name | Scott & White Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002.
A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.
South Asia is "lagging behind" in poverty and hunger reduction and is "in danger" of missing key Millennium Development Goal (MDG) targets, a U.N. official told Asian ministers gathered to discuss MDGs progress, Agence France-Presse reports. At the meeting, "senior officials told delegates from dozens of countries that global food, energy and financial crises in recent years had jeopardized progress toward achieving the goals set for 2015," the news service writes.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
› Verified 8 days ago
| Entity Name | Hillcrest Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649294323 PECOS PAC ID: 1153304456 Enrollment ID: O20040609000104 |
News Archive
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002.
A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.
South Asia is "lagging behind" in poverty and hunger reduction and is "in danger" of missing key Millennium Development Goal (MDG) targets, a U.N. official told Asian ministers gathered to discuss MDGs progress, Agence France-Presse reports. At the meeting, "senior officials told delegates from dozens of countries that global food, energy and financial crises in recent years had jeopardized progress toward achieving the goals set for 2015," the news service writes.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kindra Walker Dursteler, MD Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-8800 | Kindra Walker Dursteler, MD 2401 S 31st St, Temple, TX 76508-0001 Ph: (254) 724-2364 |
News Archive
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002.
A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.
South Asia is "lagging behind" in poverty and hunger reduction and is "in danger" of missing key Millennium Development Goal (MDG) targets, a U.N. official told Asian ministers gathered to discuss MDGs progress, Agence France-Presse reports. At the meeting, "senior officials told delegates from dozens of countries that global food, energy and financial crises in recent years had jeopardized progress toward achieving the goals set for 2015," the news service writes.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.
› Verified 8 days ago
Raagsudha Jhavar, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1605 S 31st St, Temple, TX 76508 Phone: 254-215-0100 Fax: 254-215-0636 | |
Dr. John L. Carpenter, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Farrukh Sarmad Badsha, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St # Msa1300, Temple, TX 76508 Phone: 254-935-5820 | |
Dr. Seetha Kannan, M.D Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2409 Pin Oak Dr, Temple, TX 76502 Phone: 254-774-8060 | |
Jennifer D Moran, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Douglas Randall Bretzing, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2364 | |
Dr. Patrick Ramirez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2364 Fax: 254-724-7603 |